Recombinant Rabbit Monoclonal Antibody Development Service

Leinco Technologies offers over 30 years of demonstrated success in monoclonal antibody development for demanding applications such as early discovery research, *in vivo* pre-clinical therapeutic investigations, and in vitro diagnostics. Our new recombinant rabbit monoclonal antibody development service provides a fast and efficient route to high-quality antibodies with exceptional target-specificity and affinity.

Accelerate Your Journey to High-Quality Recombinant Monoclonal Antibodies

From design of the best immunogen and screening antigen(s) for your project to characterization of antibody purified from the sequenced clone, our experts work closely with you to develop a tailored and scalable process for reliable production of antibodies with the optimal properties for your application. With our rapid development workflow and cutting-edge platform, we can produce the antibodies you need in as little as 14 weeks.

The Power of Rabbit mAb Technology

Rabbits are emerging as the preferred host species for the development of high-performance monoclonal antibodies, as they naturally generate antibodies with outstanding specificity and affinity toward a wide range of targets. Key advantages over mice and other traditional host species include:

- **Diverse immune repertoire –** Rabbits produce a much greater diversity of high-affinity antibodies with the ability to distinguish subtle structural variations such as single amino acid differences.
- **Greater immunogenicity for small molecules –** The rabbit immune system can more easily detect and mount a response to small molecules, short peptides, and other antigens that may be non-immunogenic in mice.
- **Reduced immunodominance –** Variable immunogenicity can skew the host immune system to respond more strongly to some epitopes on an antigen than others. This immunodominance is less problematic in rabbits compared to mice.

These and other unique advantages of rabbit hosts greatly expand the range of targetable epitopes and provide the foundation for rapid development of superior mAbs.

Leinco Technologies, Inc.™

excellence in early discovery research™

410 Axminister Dr.
St. Louis, MO 63026
800.538.1145
leincoglobal@leinco.com
www.leinco.com

S01-2404-A

A Streamlined Development Service

Leinco's development process takes advantage of proprietary methods for B-cell cloning, high-throughput analysis, and recombinant technology to overcome limitations of traditional hybridoma fusion and phage display platforms.

By sequencing IgG genes directly from activated clonal B-cell populations, we eliminate time-consuming hybridoma fusion and subcloning steps, for a streamlined approach with rapid turnaround times.

In addition, sequenced regions can be cloned into the backbone of choice and genetically engineered as needed for optimal performance in your application.

- High throughput development tailored to your requirements
- Scalable process
- Exceptional antibody performance and reproducibility
- High success rates
- Rapid turnaround times

Rabbit Monoclonal Antibody Development



Poised To Play a Pivotal Role

As the field continues to evolve, recombinant rabbit monoclonals are poised to transform the research, diagnostic and therapeutic landscapes.

Find out how our new service can help you stay ahead of the curve with your next project. Contact us at leincoglobal.com

Leinco Technologies, Inc.™

excellence in early discovery research™